Genedx Holdings Corp. · NASDAQ:WGS
Genedx — CM Life Sciences — SPAC Merger (February 2021)
36 slides from Genedx's SPAC merger presentation, Feb 10, 2021
Slide 1: AI-driven decision making as the standard of care
2 a Semadg e bs ° : ae 7 3 et roe \ Al-driven decision making as the = wae a + standard of care e . e F os 0 * Investor Presentation >” ° t °. a CS
Slide 2: Disclaimer
Disclaimer ‘This confidential presentation (the “presentation’) is being delivered to you by CM Life Sciences. Inc. (°CMLS? and Mount Sinai Genomics. Inc. d/b/a Semag ("Semag’) for use by Semaq and CMLS in connection with their proposed business combination and the offering of the securities of CMLS
Slide 3: Disclaimer (continued)
Disclaimer (continued) ‘Additional Information and Where to Find It / Non-Solicitation In connection with the proposed transaction, CM Life Sciences intends to file a proxy statement with the US. Securities and Exchange Commission ("SEC). The proxy statement will be sent to the stockholders of CM Li
Slide 4: Overview of CM Life Sciences
Overview of CM Life Sciences Unique combination of Eli Casdin’s investment platform and Keith Meister’s capital markets and board expertise Casdin Capital's Deep Sector Expertise * Founded in 2012, Casdin Capital has a proven track-record as investor-partners identifying and appreciating Fundamental
Slide 5: Our Vision
Our Vision To be the world leader at generating, collecting and analyzing longitudinal patient health data in partnership with patients and providers to deliver comprehensive solutions to help treat patients and enable next generation drug development
Slide 6: Revenue, Patients, Data
Revenue, Patients, Data 2020 Revenue | ’20-'23E CAGR $190MM+ | 38% Total Patients | w/Longitudinal | w/clinic-genomic Clinical Data data ~10oM | ~5M_ | ~300K Centrellis Platform Overview + Integrates proprietary data feeds including genomic insights, patient records, and public databases to create a
Slide 7: Characterizing Disease Status
Characterizing Disease Status Over Time in Patient Population Individual patient, tracked over time, defined as well or sick based on simple, binary biomarker Patients
Slide 8: Diagnoses
Diagnoses Germ line Somatic EMR Imaging Epigenome en Mewtin Hospital Consumer Based Based Environment Procedures Cost Information Device Acquired Mobile Ap) - Environmental near Physician Wearable Devices cencans Wellness Monitoring Precenneel
Slide 9: More Advanced Disease Characterization
More Advanced Disease Characterization More Advanced Still, with Transitions, Resolutions, Naive Disease Characterization Highlights Disease Transition and Subtypes > Personalized Treatments
Slide 10: From the digital universe of data to actionable insights
From the digital universe of data to actionable insights: Augmented intelligence to enable physicians and patients to make more informed decisions BIG DATA. While McKinsey and others estimate Big Data could save medicine and pharma up to $100bn annually as a result of improved efficiencies in clinic
Slide 11: Next Generation Information and Genomic Platform to Transform the Standard of Care
Next Generation Information and Genomic Platform to Transform the Standard of Care Integrating Multidimensional Data on Patients for Constructing Innovative Predictive . . Advanced Assessments Models to Drive Improved Outcomes Generate Medical Insights Lab Designed Tests Partner with Health, Systems
Slide 12: Centrellis Yields Insights That Improve Care and Drug Discovery
Centrellis Yields Insights That Improve Care and Drug Discovery Machine learning-based models for enhanced genomic risk prediction from our Traversa platform e.g. Polygenic risk scoring Centrellis™ Deriving population-health insights from genomic data to differentiate 2) our industry-leading tests e
Slide 13: Unique and Actionable Insights Transform the Patient Treatment Paradigm
Unique and Actionable Insights Transform the Patient Treatment Paradigm om Patients & Physicians Sample Tracking, Discrete Result Generation, and Ingestion froncmem om enisorece ae ——= Long-Term Monitoring Personalized C7 } Ongoing >| including genetic markers, Trial Matching om ! —_ therapies, and
Slide 14: Through Our Platform We Develop Long-Term Relationships with Patients and Providers
Through Our Platform We Develop Long-Term Relationships with : Patients and Providers ae INFORMATION-RICH GENOMIC SOLUTIONS WOMEN'S HEALTH SOLUTIONS —- ONCOLOGY SOLUTIONS —————— _ POPULATION HEALTH — SI teen ay CEE TORI Noninvasive Prenatal Screening Informatics Tools * Leveraging Tawar? lio-omior E
Slide 15: Revenue by Segment 2020-2023
REVENUE BY SEGMENT 2020-2023 ($M) ~=-——_______ Segment CAGR 2020-2023 Secondary Data WH Direct Oncology Insights* WH HS Partners, 164% 257% COVID-19 Pharma 5 IB Pharma Partnerships a Pananstes ee HB Onc HS Partners a $504 129% I Onc Direct c AGR oo B% VT Il Secondary Data Insights ee "2021-2023 CAGR
Slide 16: Revenue Mix Evolution is Driving Meaningful Gross Margin Expansion
Revenue Mix Evolution is Driving Meaningful Gross Margin Expansion REVENUE MIX I Direct Testing 1% i Partnerships Ml Repeat Insights 3% 4% 86 % 2020E 2021E 2022E 2023E Total Revenue $190 $265 $360 $504 GROSS MARGIN 54% 1% 32% 22% 2020E 2021E 2022E 2023E Accelerating biopharma and partnership adoptio
Slide 17: Competitor Benchmarking
Competitor Benchmarking [— 2021E to 2023E Revenue CAGR 7 46.7% Median: 32.1% 37.9% 321% 34.7% | 24.6% 23.1% L || Natera ” Invitae Exact Guardant Adaptive sema4 Sciences Health Biotechnologies [—— 2022E Revenue $2,193 $700 $360 $585 $508 $205 — | | i a —= semad Natera Invitae Exact Guardant Adaptive
Slide 18: Expanding Margin Profile
EXPANDING MARGIN PROFILE Driven by Improving Product Volume & Mix HEALTH SYSTEM & PHARMA PARTNERSHIPS Provide Partnership Revenue with Attractive Unit Economics CLEAR PATH TO PROFITABILITY with Strong Operating Leverage TOTAL REVENUE ($M) CAGR: 38% _——— $504 $190 2020 2023 GROSS MARGIN| ——— 43,161 e
Slide 19: Accelerating Health System Partnerships Will Underpin Our Growth
Accelerating Health System Partnerships Will Underpin Our Growth: Revenue, Patients, Data PLAN FOR EXPANSION Data Features growing 100x 6 * Sign up incremental systems \ leveraging value of state of the art ' Recruit and build health genomic testing solutions at no cost, 1 30M+ Patients system partn
Slide 20: Centrellis platform has utility across the spectrum of disease & wellness
Centrellis platform has utility across the spectrum of disease & wellness to transform standard of care Semazg is filling a white space to un/fy the engagement with stakeholders across the healthcare ecosystem and reflects a novel approach where significant investment has yet to be seen. fr sema4 Ad
Slide 21: Standard of Care Focus
Standard of Care Focus Clinical Clinical Reports Trials K Enhanced Data Feed Laboratory Clinical Decision Support Centrellis™ Capability Key: @ Poputation-health insights @ Engagement of complex data and insights nr een (ersten reacerdof care neces Consumer Focus Population Health Models Centrellis™
Slide 22: Four Foundational Pillars Will Enable Us to Achieve Our Vision
Four Foundational Pillars Will Enable Us to Achieve Our Vision We are building a unique data ecosystem and platform containing deep data from increasing numbers of consenting patients (currently millions) engaged by our platform or partnered health systems 0060 STATE-OF-THE-ART ACCESS & DEEP & UNIQU
Slide 23: Case Study: Traversa Platform
Case Study: Traversa Platform A COMPREHENSIVE EXOME/WHOLE GENOME FRAMEWORK TO ADAPT AT THE RATE OF LEARNING <4) po BB . Polygenic risk Carrier Pharmacogenomics scores screening & && # a Y a. [e) 5 cancer screening cancer initialorde Generate Data 1X Automated / Query Data ae Health By Rich Data Set
Slide 24: Insights Leveraged to Improve Risk Assessment & Patient Care
Insights Leveraged to Improve Risk Assessment & Patient Care = Patients & Physicians Patient Records from Health Systems == Sema4 Proprietary Test Offerings ela Centrellis Al Tinvarea Cee UIRLEKOR. Combines public and proprietary data across an Expanded Carrier Screen Hereditary Cancer Testing expan
Slide 25: Case Study: Connecting With Patients Across the Pregnancy Journey
Case Study: Connecting With Patients Across the Pregnancy Journey Week 19 7) Your baby is about the length of a small ‘chipmunk sema4 it Pregnancy Journey Week 19: Your body changes. nc ‘oupashoe sizer two. 120/90 - 140/75 vom Your Medical Results Patients & Physicians sema4 Pregnancy Journey Week 1
Slide 26: Our Solutions
OUR SOLUTIONS tv) State of the art information-rich genomic platform to enable: Y¥ Cancer profiling v¥ Population health screening v Women's health v_ Drug safety Based on the integration of 2 proprietary platforms: genomics and informatics Provide patient-level insights to elevate standard of care
Slide 27: Case Study: Health System Partnerships
Case Study: Health System Partnerships | Health Systems Each partne rts wi MSA, and seve: (- SYSTEM DETAILS AREAS OF FOCUS FUTURE GROWTH ——— > + 5 local hospitals and 130 clinical MSA, Steering Committee and 2 Initial Scoping SOWs to Grow Relationship locations SOWs Signed + Population Health Screen
Slide 28: Our Value Proposition to Pharma Partners Across the Drug Lifecycle
Our Value Proposition to Pharma Partners Across the Drug Lifecycle DISCOVERY Research LEAD IDENTIFICATION Drive increased probability of success and terminate bad molecules sooner Systems bio on rich data to ID drug targets / Immune assays / bio analysis, in vitro / in vivo models (with biomarkers,
Slide 29: Case Studies: Pharma Partnerships
Case Studies: Pharma Partnerships e Pharma Partners Pharma A Pharma B Pharma C ee. —4 \ , iA - / eo, a d = + Five-year multiscale study follows over a thousand + Provide hundreds of cancer sample sequencing + Leveraging deeply-curated clinico-genomic patients using advanced network modeling to make
Slide 30: Monetize Information Platform
MONETIZE INFORMATION PLATFORM Matching patients to products and services TO QUERY FOR INSIGHTS (moving beyond providers and life science) GENOMIC TESTING Differentiated information-rich genomic SOLUTIONS REVENUE testing platform that provides a best-in-class service and workflow model — Delivering V
Slide 31: Our Team
Our Team . © Founder and CEO of Semag and also serves as the Dean for Precision Medicine and Mount Sinai Professor in Predictive Health “8. Sage and Computational Biology at the Icahn School of Medicine at Mount Sinai He was previously Founding Director of the Icahn Institute for Genomics and Multis
Slide 32: Use of Proceeds: Creating Inflection Points in Value Creation
Use of Proceeds: Creating Inflection Points in Value Creation Filling the gaps and expanding our platform and uptake into systems - investment in the components of a holistic precision medicine platform requires significant capital to scale into the market. Reg. | Wa lin. Utiity) Capital Investments
Slide 33: Priority deals considering Franchise needs and timeframe, targets, and conviction
Priority deals considering Franchise needs and timeframe, targets, and convic rN Fitness ULTRA HIGH - nearly Tracker TRANSFORMATIV 5 aco. | / Bats EDEAL > . CEE \ Chronic Disease ~ 7 ; Mgmt. Co. HIGH -- M&A g ela EET Q Tracking of Ss Disease to < Match with iS ei 8 g veo 3 lution MEDIUM ~~ = INCUBAT
Slide 34: Transaction Rationale and Summary
Transaction Rationale and Summary Semag opportunity encompasses multiple validated markets, supporting massive value creation * Create a category-defining healthcare data intelligence company founded and led by a team of world class data scientists and engineers + Differentiated platform and technol
Slide 35: Transaction Overview
Transaction Overview ($ in Millions) Sues Forma Valuation CMLS Cash in trust $443 Share Price $10.00 PIPE Investment 350 Pro Forma Shares Outstanding 257.1 Sellers Equity 1,667 ‘Equity Value $2,571 Existing Cash on Balance Sheet 92 (+) Debt - Total $2,552 (-) Pro Forma Cash 500 Enterprise Value 2,07
Slide 36: eee) ) 1] ba OR
d eee) ) 1] ba OR A OSX oe @ iho imum © ry